The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults ...

A program that delivered in-home visits from a trained paramedic team to people with heart failure did not significantly reduce 30-day hospital ...

An intensive three-drug regimen of heart medications did not significantly impact the rate of serious cardiovascular events ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients ...

Eli Lilly reports 94% Lp(a) reduction with lepodisiran in Phase 2 trials, targeting inherited heart disease risk.

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they underwent open-heart bypass surgery (CABG) or a less invasive procedure called ...

Advances in PCI over the past decade mean the procedure can now approximate results only previously achieved with open-heart bypass surgery, new data show.

Despite showing no overall benefit, the in-home paramedic visit appeared to help women avoid readmissions more than men.